DFJ InCube Ventures is a life science venture capital firm focused on investing in extraordinary innovations that solve unmet clinical
Business Model:
Revenue: $13.9M
Employees: 2-10
Address: 2051 Ringwood Ave
City: San Jose
State: CA
Zip: 95131
Country: US
DFJ InCube Ventures is a life science venture capital firm focused on investing in extraordinary innovations that solve unmet clinical needs for large patient populations. The fund is built around Mir Imran, one of the leading healthcare innovators. Under Mir&s;s leadership, DFJ InCube Ventures has access to ventures formed by InCube Labs – a multi-disciplinary research lab that has been a highly productive source of medical device companies. Mir and InCube Labs have formed 20 companies over the past 25 years, creating a series of multi-billion dollar markets along the way. In addition to Mir, proven healthcare entrepreneurs and investors Andrew Farquharson and Wayne Roe serve as managing partners of the fund. DFJ InCube Ventures managing partners work closely with entrepreneurs to commercialize breakthroughs grounded in clinical need and protected by strong intellectual property. Their experienced team also actively helps young companies mitigate technical, clinical and reimbursement risks. Most importantly, the team collaborates with entrepreneurs to determine the most effective path for bringing innovations to life in a way that dramatically improves clinical outcomes. The fund&s;s current portfolio includes companies that are developing novel treatment approaches in clinical areas such as atrial fibrillation, epilepsy, gastro intestinal surgery, iron-deficiency anemia, hemorrhagic stroke and metabolic disorders.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2006 | Action Pharma | Series A | 6M |
5/2012 | BodyMedia | Venture Round | 12M |
12/2021 | Tasso | Series B | 0 |
6/2015 | PLEXUSS | Angel Round | - |
12/2018 | WhiteSwell | Series B | 30M |
4/2012 | Intrapace | Venture Round | 0 |
11/2020 | Metagenomi | Series A | 0 |
8/2019 | Metagenomi | Series A | 0 |
7/2013 | Rani Therapeutics | Series B | 0 |
9/2015 | Channel Medsystems | Series C | 0 |
2/2011 | Sonoma Orthopedics | Series D | 22M |
2/2019 | Metagenomi | Seed Round | - |
11/2009 | Spinal Modulation | Series C | 27.4M |
8/2016 | Fe3 Medical | Series B | 3.5M |
5/2015 | Rani Therapeutics | Series C | 0 |
5/2013 | Channel Medsystems | Series B | 9.8M |
1/2021 | Neuros Medical | Series B | 0 |
6/2011 | Spinal Modulation | Series D | 0 |
12/2021 | Tasso | Series B | 0 |
1/2021 | Neuros Medical | Series B | 0 |
11/2020 | Metagenomi | Series A | 0 |
8/2019 | Metagenomi | Series A | 0 |
2/2019 | Metagenomi | Seed Round | - |
12/2018 | WhiteSwell | Series B | 0 |
8/2016 | Fe3 Medical | Series B | 0 |
9/2015 | Channel Medsystems | Series C | 0 |
6/2015 | PLEXUSS | Angel Round | - |
5/2015 | Rani Therapeutics | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|